BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

About BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BCRX
  • CUSIP: 09058V10
  • Web:
  • Market Cap: $412.55 million
  • Outstanding Shares: 80,420,000
Average Prices:
  • 50 Day Moving Avg: $6.36
  • 200 Day Moving Avg: $6.49
  • 52 Week Range: $2.60 - $9.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.13
  • P/E Growth: -0.40
Sales & Book Value:
  • Annual Revenue: $30.97 million
  • Price / Sales: 13.32
  • Book Value: $0.48 per share
  • Price / Book: 10.69
  • EBIDTA: ($39,640,000.00)
  • Net Margins: -313.02%
  • Return on Equity: -296.19%
  • Return on Assets: -68.58%
  • Debt-to-Equity Ratio: 6.35%
  • Current Ratio: 1.25%
  • Quick Ratio: 1.21%
  • Average Volume: 1.83 million shs.
  • Beta: 3.67
  • Short Ratio: 3.6

Frequently Asked Questions for BioCryst Pharmaceuticals (NASDAQ:BCRX)

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.01. The company earned $9.40 million during the quarter, compared to the consensus estimate of $6.13 million. BioCryst Pharmaceuticals had a negative net margin of 313.02% and a negative return on equity of 296.19%. The firm's quarterly revenue was up 95.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. View BioCryst Pharmaceuticals' Earnings History.

When will BioCryst Pharmaceuticals make its next earnings announcement?

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for BioCryst Pharmaceuticals.

Where is BioCryst Pharmaceuticals' stock going? Where will BioCryst Pharmaceuticals' stock price be in 2017?

9 brokerages have issued 12-month target prices for BioCryst Pharmaceuticals' shares. Their predictions range from $6.00 to $11.00. On average, they expect BioCryst Pharmaceuticals' share price to reach $8.50 in the next year. View Analyst Ratings for BioCryst Pharmaceuticals.

What are analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:

  • 1. Needham & Company LLC analysts commented, "Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."" (5/19/2017)
  • 2. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (5/8/2017)

Who are some of BioCryst Pharmaceuticals' key competitors?

Who owns BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include VHCP Management II LLC (7.55%), Vanguard Group Inc. (6.24%), D. E. SHAW & COMPANY , L.P. (5.00%), RA Capital Management LLC (4.34%), FLYNN JAMES E (4.25%) and State Street Corp (2.83%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Bros Advisors Lp Baker, Jon P Stonehouse, Thomas R Staab II, William P Sheridan and Yarlagadda S Babu. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

Who sold BioCryst Pharmaceuticals stock? Who is selling BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Wells Fargo & Company MN, UBS Group AG, SG Americas Securities LLC, ProShare Advisors LLC, Alliancebernstein L.P., KCG Holdings Inc. and TIAA CREF Investment Management LLC. Company insiders that have sold BioCryst Pharmaceuticals stock in the last year include Alane P Barnes, Bros Advisors Lp Baker, Thomas R Staab II and Yarlagadda S Babu. View Insider Buying and Selling for BioCryst Pharmaceuticals.

Who bought BioCryst Pharmaceuticals stock? Who is buying BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bogle Investment Management L P DE, FMR LLC, RA Capital Management LLC, Jennison Associates LLC, Emory University, Geode Capital Management LLC and Wellington Management Group LLP. View Insider Buying and Selling for BioCryst Pharmaceuticals.

How do I buy BioCryst Pharmaceuticals stock?

Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioCryst Pharmaceuticals stock cost?

One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $5.13.

Analyst Ratings

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (?)
Ratings Breakdown: 2 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $8.50 (65.69% upside)

Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Needham & Company LLCReiterated RatingHoldMediumView Rating Details
5/6/2017Noble FinancialReiterated RatingBuyHighView Rating Details
3/1/2017HC WainwrightReiterated RatingBuy$10.00N/AView Rating Details
2/28/2017Jefferies Group LLCBoost Price TargetPositive$3.50 -> $6.00N/AView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$11.00N/AView Rating Details
2/13/2017Piper Jaffray CompaniesReiterated RatingOverweight$8.00N/AView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
12/16/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$10.00N/AView Rating Details
8/5/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00N/AView Rating Details
11/11/2015Bank of America CorpDowngradeNeutral -> Underperform$12.00 -> $10.00N/AView Rating Details
11/10/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformN/AView Rating Details
8/10/2015MLV & Co.Reiterated RatingBuy$15.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Earnings by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Earnings History by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.20)($0.19)$6.13 million$9.40 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.06)$4.13 million$9.00 millionViewListenView Earnings Details
11/7/2016Q316($0.24)($0.16)$5.94 million$7.80 millionViewListenView Earnings Details
8/4/2016Q216($0.26)($0.22)$3.92 million$4.80 millionViewN/AView Earnings Details
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.20)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
2017 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.14)($0.14)($0.14)
Q2 20171($0.17)($0.17)($0.17)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)


Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 76.88%
Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Thomas R Staab IICFOSell3,250$9.20$29,900.00View SEC Filing  
3/10/2017Thomas R Staab IIInsiderSell3,250$9.06$29,445.00View SEC Filing  
3/8/2017Thomas R Staab IIInsiderSell6,500$8.43$54,795.00View SEC Filing  
3/6/2017Thomas R Staab IIInsiderSell3,250$7.90$25,675.00View SEC Filing  
12/19/2016Thomas R Staab IIInsiderSell3,250$7.45$24,212.50View SEC Filing  
9/14/2016Alane P BarnesVPSell8,357$4.27$35,684.39View SEC Filing  
8/25/2016Yarlagadda S BabuVPSell30,000$4.06$121,800.00View SEC Filing  
8/16/2016Bros. Advisors Lp BakerMajor ShareholderSell4,046,590$5.00$20,232,950.00View SEC Filing  
8/12/2016Thomas R Staab IIInsiderSell5,864$5.18$30,375.52View SEC Filing  
8/9/2016Thomas R Staab IIInsiderSell14,577$4.43$64,576.11View SEC Filing  
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.75View SEC Filing  
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.00View SEC Filing  
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.65View SEC Filing  
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.00View SEC Filing  
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.00View SEC Filing  
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72View SEC Filing  
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00View SEC Filing  
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00View SEC Filing  
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.85View SEC Filing  
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.00View SEC Filing  
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateHeadline logoBioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Buy" from Brokerages - May 23 at 2:20 PM logoBioCryst Pharmaceuticals (BCRX) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow - May 22 at 10:49 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Rating Reiterated by Needham & Company LLC - May 19 at 5:54 PM logoImplied Volatility Surging for BioCryst (BCRX) Stock Options - May 16 at 12:21 PM logoZacks: Analysts Anticipate BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Quarterly Sales of $5.39 Million - May 11 at 9:36 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Expected to Announce Earnings of -$0.19 Per Share - May 10 at 12:10 AM logoNoteworthy Tuesday Option Activity: AGN, EA, BCRX - May 9 at 3:52 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Stock Rating Lowered by Zacks Investment Research - May 8 at 5:28 PM logoBioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 7 at 4:04 PM logoToday's Research Reports on Biotech Stocks to Watch: BioCryst Pharmaceuticals and Keryx Biopharmaceuticals - May 5 at 3:52 PM logoEdited Transcript of BCRX earnings conference call or presentation 4-May-17 3:00pm GMT - May 5 at 2:01 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Issues Quarterly Earnings Results - May 4 at 11:06 PM logoBioCryst Reports First Quarter 2017 Financial Results - May 4 at 3:57 PM logoBioCryst reports 1Q loss - May 4 at 3:57 PM logoInvestor Network: BioCryst Pharmaceuticals, Inc. to Host Earnings Call - May 4 at 3:57 PM logoBioCryst Pharmaceuticals (BCRX) Receiving Somewhat Positive Press Coverage, Study Shows - May 4 at 1:48 PM logoZacks Investment Research Lowers BioCryst Pharmaceuticals, Inc. (BCRX) to Hold - May 2 at 6:26 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) to Release Quarterly Earnings on Thursday - May 2 at 11:24 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Upgraded to Buy at Zacks Investment Research - May 1 at 8:16 PM logoFavorable Press Coverage Very Likely to Affect BioCryst Pharmaceuticals (BCRX) Stock Price - May 1 at 12:42 PM logoPositive Media Coverage Very Likely to Impact BioCryst Pharmaceuticals (BCRX) Share Price - April 28 at 11:56 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Buy" from Analysts - April 28 at 4:38 PM logoSomewhat Positive News Coverage Very Likely to Impact BioCryst Pharmaceuticals (BCRX) Share Price - April 25 at 2:59 PM logo Analysts Expect BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Quarterly Sales of $5.89 Million - April 21 at 4:44 PM logoSomewhat Positive Press Coverage Very Likely to Affect BioCryst Pharmaceuticals (BCRX) Stock Price - April 21 at 12:03 PM logoWill Stryker (SYK) Deliver a Beat this Earnings Season? - April 20 at 3:55 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Upgraded to Buy by Zacks Investment Research - April 18 at 4:48 PM logoBioCryst Pharmaceuticals (BCRX) Earns News Impact Score of 0.22 - April 18 at 1:02 PM logoBioCryst Pharmaceuticals' (BCRX) Hold Rating Reiterated at Needham & Company LLC - April 18 at 7:27 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Short Interest Update - April 17 at 12:36 PM logoPositive Press Coverage Extremely Likely to Impact BioCryst Pharmaceuticals (BCRX) Stock Price - April 15 at 12:33 PM logoNeedham & Company LLC Reaffirms "Hold" Rating for BioCryst Pharmaceuticals, Inc. (BCRX) - April 13 at 5:40 PM logoNeedham and Company Reiterates Hold Rating on BioCryst Pharma (BCRX) Following BCX7353 Development ... - - April 13 at 4:00 PM logoAfter announcing a $45M public offering, BioCryst to launch new trial - April 13 at 4:00 PM logoBioCryst Pharma (BCRX) BCX7353 Expands Development to Explore Treatment for Acute HAE Attacks - April 12 at 11:30 AM logoBioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks - April 12 at 11:30 AM logoBioCryst to receive royalties from cancer treatment approved in Japan - April 7 at 8:25 AM logoBioCryst Pharmaceuticals (BCRX) Down as Drug Receives Japanese Nod - April 3 at 4:16 PM logoBioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan - April 3 at 4:16 PM logoStocks of companies with Raleigh-Durham area HQ make a comeback in March - April 3 at 4:16 PM logoShort Interest in BioCryst Pharmaceuticals, Inc. (BCRX) Grows By 17.4% - March 26 at 7:17 AM logoInsider Selling: BioCryst Pharmaceuticals, Inc. (BCRX) CFO Sells 3,250 Shares of Stock - March 22 at 11:40 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Downgraded to "Hold" at Zacks Investment Research - March 20 at 5:39 PM logoBIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and - March 17 at 9:31 PM logoBIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - March 15 at 4:09 PM logoBioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue? - March 15 at 4:09 PM logoBioCryst Pharmaceuticals (BCRX) Presents At Barclays Global Healthcare Conference 2017 - March 14 at 8:47 PM logoBioCryst Pharma (BCRX) Prices 5.29M Share Offering at $8.50 - March 10 at 9:44 PM logo3:08 am BioCryst Pharma prices offering of 5,294,118 shares of its common stock at $8.50 per share - March 10 at 4:41 PM logoBioCryst Pharmaceuticals Prices Public Offering of Common Stock - March 9 at 9:26 PM



BioCryst Pharmaceuticals (BCRX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff